TY - JOUR
T1 - The resurgence of monkeypox
T2 - Epidemiology, clinical features, and public health implications in the post-smallpox eradication era
AU - Singh, Parminder
AU - Sridhar, Sathvik Belagodu
AU - Shareef, Javedh
AU - Talath, Sirajunisa
AU - Mohapatra, Priyanka
AU - Khatib, Mahalaqua Nazli
AU - Ballal, Suhas
AU - Kaur, Mandeep
AU - Nathiya, Deepak
AU - Sharma, Shilpa
AU - Siva Prasad, G. V.
AU - Sinha, Aashna
AU - Varma, Amit
AU - Bushi, Ganesh
AU - Gaidhane, Abhay M.
AU - Satapathy, Prakasini
AU - Shabil, Muhammed
AU - Sah, Renu
AU - Al-Tawfiq, Jaffar A.
AU - Sah, Ranjit
AU - Rodriguez-Morales, Alfonso J.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/12
Y1 - 2024/12
N2 - The recent global resurgence of Mpox (formerly monkeypox), primarily transmitted via close contact and respiratory droplets, highlights a significant shift in its epidemiology, particularly among men who have sex with men (MSM). This resurgence underscores the need for robust public health responses and improved surveillance. This comprehensive review of current literature focuses on recent outbreaks, virology, and available treatments. Epidemiological data were gathered from various international health reports and analysed to understand transmission dynamics and outbreak patterns. Mpox, characterised by symptoms like fever and rash, has shown variable clinical presentations, particularly among immunocompromised individuals. Recent outbreaks have prompted the development of new diagnostic methods and treatments, including antivirals like Tecovirimat and vaccines such as MVA-BN. Studies have demonstrated the effectiveness of these vaccines in preventing infection, which is crucial for outbreak containment. The global response to the Mpox resurgence requires integrated strategies combining vaccination, antiviral treatments, and public health policies tailored to high-risk populations. Future efforts should focus on vaccine distribution equity and enhancing diagnostic capabilities to effectively manage and mitigate the impact of Mpox.
AB - The recent global resurgence of Mpox (formerly monkeypox), primarily transmitted via close contact and respiratory droplets, highlights a significant shift in its epidemiology, particularly among men who have sex with men (MSM). This resurgence underscores the need for robust public health responses and improved surveillance. This comprehensive review of current literature focuses on recent outbreaks, virology, and available treatments. Epidemiological data were gathered from various international health reports and analysed to understand transmission dynamics and outbreak patterns. Mpox, characterised by symptoms like fever and rash, has shown variable clinical presentations, particularly among immunocompromised individuals. Recent outbreaks have prompted the development of new diagnostic methods and treatments, including antivirals like Tecovirimat and vaccines such as MVA-BN. Studies have demonstrated the effectiveness of these vaccines in preventing infection, which is crucial for outbreak containment. The global response to the Mpox resurgence requires integrated strategies combining vaccination, antiviral treatments, and public health policies tailored to high-risk populations. Future efforts should focus on vaccine distribution equity and enhancing diagnostic capabilities to effectively manage and mitigate the impact of Mpox.
KW - Antiviral treatment
KW - Epidemiology
KW - Mpox
KW - Public health response
KW - Transmission
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85205726182&partnerID=8YFLogxK
U2 - 10.1016/j.nmni.2024.101487
DO - 10.1016/j.nmni.2024.101487
M3 - Artículo de revisión
AN - SCOPUS:85205726182
SN - 2052-2975
VL - 62
JO - New Microbes and New Infections
JF - New Microbes and New Infections
M1 - 101487
ER -